Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VelosBio Inc.
Big Pharma companies are remaining ‘disciplined’ about their M&A deals, with Merck & Co apparently shying away from a $40bn gamble on Seagen, but the need for replenished pipelines remains.
A buyout of Seagen would boost Merck & Co’s goal of becoming the dominant player in oncology by 2025, but the deal is said to be far from done.
Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
- Large Molecule